Rna Interference Gene Targeting
Rna Interference Gene Targeting - Related Videos
01:23
RNA Interference
0 Views •
2019
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated. This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
09:06
RNA Interference in Ticks
0 Views •
Cited by 49 •
2011
A method for RNA interference (RNAi) by injection of dsRNA into unfed ticks is described. RNAi is the most widely used gene-silencing technique in ticks where the use of other methods of genetic manipulation has been limited.
07:27
CRISPR Interference-Based Gene Silencing: A Technique for Targeted Repression of Gene Function in Pathogenic Leptospira
0 Views •
2025
This video demonstrates a CRISPR interference-based gene silencing in pathogenic Leptospira. Targeted repression of gene expression using a CRISPR/Cas system that blocks mRNA formation helps identify candidate genes for pathological and pharmacological studies.
13:10
DNA Vector-based RNA Interference to Study Gene Function in Cancer
0 Views •
Cited by 26 •
2012
RNA interference (RNAi) possesses many advantages over gene knockout and has been broadly used as a tool in gene functional studies. The invention of DNA vector-based RNAi technology has made long term and inducible gene knockdown possible, and also increased the feasibility of gene silencing in vivo.
11:22
Using RNA-mediated Interference Feeding Strategy to Screen for Genes Involved in Body Size Regulation in the Nematode C. elegans
0 Views •
Cited by 11 •
2013
We demonstrate how to use the RNAi feeding technique to knock down target genes and score body size phenotype in C. elegans. This method could be used for a large scale screen to identify potential genetic components of interest, such as those involved in body size regulation by DBL-1/TGF-β signaling.
FAQs
Specificity comes from the guide RNA strand associated with the RNA-induced silencing complex. Its sequence base-pairs with a complementary messenger RNA, directing the complex toward that transcript rather than unrelated RNA. Once recognized, the target message may be cleaved or prevented from supporting translation, reducing production of the corresponding protein.
Both outcomes follow guide-directed recognition of the complementary messenger RNA, but the source material identifies cleavage and translational repression as alternative consequences rather than assigning them to separate experimental conditions. This distinction matters because either outcome can lower gene expression, while the measured result is reduced production of the associated protein or gene product.
A silencing strategy must reach the relevant tissue, act in the intended cellular setting, and maintain its effect long enough to be useful. Delivery determines access, tissue specificity influences where silencing occurs, and durability affects how long reduced expression persists. These variables therefore shape both therapeutic performance and the interpretation of disease-gene studies.
A study begins by selecting a disease-associated gene and directing silencing machinery toward its messenger RNA. Cellular processing generates small interfering RNAs, and one strand guides recognition of the chosen transcript. Investigators then evaluate the resulting reduction in gene expression or protein production, using the outcome to examine the gene’s function in disease.
The approach is particularly relevant when researchers want to lower a harmful protein or investigate the function of a disease gene that may be difficult to inhibit with conventional drugs. Instead of requiring a conventional inhibitor to act on the protein, the strategy reduces expression upstream at the messenger RNA level, broadening the range of potential targets.
Evaluation should consider whether the intended gene or harmful protein is reduced, where the effect occurs, and how long it lasts. Researchers must also examine unintended gene silencing, because activity against unintended transcripts can compromise selectivity and safety. In medical development, these results are interpreted alongside delivery and tissue-specific performance rather than expression reduction alone.